Navigation Links
Orthomimetics Secures CE Mark Approval for Chondromimetic
Date:1/14/2009

CAMBRIDGE, England, January 14 /PRNewswire/ -- This approval enables the company to market its line of bioresorbable implants for bone and/or soft tissue repair in the EU. Orthomimetics' family of products was developed during a groundbreaking collaboration between the University of Cambridge and the Massachusetts Institute of Technology.

Chondromimetic is a novel off-the-shelf implant that helps to support the repair of defects involving both articular cartilage and bone - defects that can result from sports injuries, surgical intervention and other trauma. Articular cartilage damage and subsequent degeneration of the underlying bone are known to be a major cause of arthritis in young individuals.

CE-mark approval enables the company to market Chondromimetic in Europe, and comes earlier than originally forecast at the time of the company's December 2006 Series A financing. Orthomimetics will immediately launch a comprehensive post-market clinical-trial program for Chondromimetic, and is currently negotiating distribution agreements for key European territories. The company will pursue additional approvals in other global territories throughout 2009.

Commenting on the CE Mark approval, Dr Andrew Lynn, CEO of Orthomimetics, said:

"Orthomimetics is extremely pleased to be able to make Chondromimetic available for surgeons and patients in Europe. This approval is the result of a tremendous amount of hard work on the part of our surgeon advisors, scientific collaborators, and - most of all - our professional, dedicated team. We look forward to making Chondromimetic a clinical and commercial success."

Editors Notes:

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: http://www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com


'/>"/>
SOURCE Orthomimetics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. DFine Secures $30 Million in Series D Funding
3. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
4. Cohera Medical Secures $16.1 Million in Series B Financing
5. Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel
6. Almost Family Secures $75 Million Revolving Credit Facility
7. 1,000th Uninsured Virginia Patient Secures Access to Quality Medical Care Through Virginia Cares Uninsured Program (VCUP)
8. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
9. Global Med Technologies(R), Inc. Secures $6 Million Credit Facility From Silicon Valley Bank for Inlog Acquisition
10. PSS Systems Secures $18 Million in Financing
11. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology: